Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company developing a new class of centrally-acting medication to treat hypertension and heart failure, announced today that it has won the 2017 Galien MedStartUp award for "Best innovative clinical study design".
"We are extremely proud to be recognised along with our research partner, Medpace, by this prestigious award from the Galien Foundation. Our clinical trial, which just started in the United States, gives new hope to millions of patients suffering from complicated or even resistant hypertension. That's why we called it NEW-HOPE—our study is aimed at segments of the population who currently lack treatment options. Our goal is to quickly provide these patients with an effective solution in the form of our drug candidate, QGC001. This is the first example of a new class of centrally acting antihypertensive medication", says Lionel Ségard, Chief Executive Officer of Quantum Genomics.
The phase II NEW-HOPE clinical study, designed to evaluate the efficacy of QGC001 in the treatment of high blood pressure, began in the United States in late September. The study is being conducted across twenty-five hospitals and will recruit 250 hypertensive patients who are either overweight or obese. Half of the patients will be ethnic minorities (African-American, Hispanic, or Asian), who are especially vulnerable to complicated or even resistant hypertension.
Dr. Catherine Llorens-Cortes, a specialist in the brain renin–angiotensin system and co-inventor of the brain aminopeptidase A inhibitors currently being developed by Quantum Genomics, has already received the Galien France Award (2014) in recognition for her research. She directs the Inserm "Central Neuropeptides and Hydric and Cardiovascular Regulations" laboratory at Collège de France.
Through MedStartUp, the Galien Foundation, which was first created in 1970, encourages and recognises international partnerships between innovative French and North American companies geared towards innovation and excellence.
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company specialising in the development of a new class of cardiovascular drugs based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on its 20-plus years of basic and clinical research at some of the largest French laboratories (The French National Institute of Health and Medical Research (INSERM), the French National Centre for Scientific Research (CNRS), the Collège de France, and Paris-Descartes University). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant,
cases of arterial hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for congestive heart failure (one in two patients diagnosed with congestive heart failure dies within five years).
Based in Paris and New York, the company is listed on the Euronext Growth exchange in Paris (FR0011648971 - ALQGC) and trades on the OTCQX market in the United States (symbol: QNNTF). For more information, visit www.quantum-genomics.com. Follow us on Twitter and Linkedin.
Chairman and CEO
+33 (0)1 85 34 77 70
CFO - Investor Relations
+33 (0)1 85 34 77 70 - email@example.com
Media Relations and Scientific Communications
+33 (0)6 50 92 21 56 - firstname.lastname@example.org
+33 (0)6 85 82 41 95 - email@example.com
|Edison Advisors (U.S.)|
+1 (646) 653-7035 - firstname.lastname@example.org